OPKO Health Inc (OPK)

6.04
0.02 0.33
NASDAQ : Health Care
Prev Close 6.02
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.85 / 12.15
Avg Volume 4.35M
Exchange NASDAQ
Shares Outstanding 559.40M
Market Cap 3.34B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Announces Appointment Of Three Directors To The Board

Xenetic Biosciences Announces Appointment Of Three Directors To The Board

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Jim Cramer says we must watch the 'selfie generation' because it's changing the ways companies do business.

OPKO Health Reports Second Quarter 2017 Business And Financial Results

OPKO Health Reports Second Quarter 2017 Business And Financial Results

Conference call begins at 4:30 p.m. Eastern time today

Eloxx Pharmaceuticals Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million

Eloxx Pharmaceuticals Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million

Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis

Xenetic Biosciences Announces Adjournment Of Annual Meeting Of Stockholders Until Wednesday, August 16, 2017

Xenetic Biosciences Announces Adjournment Of Annual Meeting Of Stockholders Until Wednesday, August 16, 2017

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPK: Insiders vs. Shorts

The most recent short interest data was recently released for the 06/15/2017 settlement date, and OPKO Health Inc is one of the most shorted stocks of the Russell 3000, based on 19.31 "days to cover" versus the median component at 4.94. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Biotech Movers: Paratek, Opko, Endo

Biotech Movers: Paratek, Opko, Endo

Shares of Paratek Pharmaceuticals, Opko Health and Endo International were among the biotech stock movers in premarket trading on June 30.

Xenetic Biosciences Commences Patient Enrollment In Phase 2 Study Evaluating XBIO-101 In Conjunction With Progestin Therapy For The Treatment Of Endometrial Cancer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health Announces KDIGO Clinical Practice Guideline Update On CKD-MBD

Updated Guideline Highlights the Limitations of Current Treatments for Secondary Hyperparathyroidism in Patients with Stage 3 or 4 Chronic Kidney Disease and Acknowledges Rayaldee as a Novel Vitamin D Prohormone

OPKO'S GeneDx Extends Relationship With University Of California Health For Genetic And Molecular Testing

OPKO Helps Expand UC Health's leadership at the forefront of precision medicine

Xenetic Biosciences Receives Program Update From Partner Shire's Phase 1/2 Study Evaluating SHP656 In Development As A Long-acting Treatment For Hemophilia A

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health's 4Kscore® Test Highlighted In Podium Presentation At 112th American Urological Association Annual Meeting

Prospective study conducted at Veteran Affairs hospitals confirms 4Kscore accurately predicts aggressive prostate cancer

Insiders Are Loading Up on GE, Twilio & More

Insiders Are Loading Up on GE, Twilio & More

Insiders at General Electric, Twilio and three other companies have been snapping up shares of their own stock lately.

Xenetic Biosciences Reports 2017 First Quarter Financial Results And Provides Business Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

CORRECTION -- OPKO Health Inc.

Xenetic Biosciences To Host 2017 First Quarter Update Conference Call

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Presents Case Study Of PolyXen™ Platform Technology At The 13th Annual Protein Engineering Summit (PEGS) Boston

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

TheStreet Quant Rating: D+ (Sell)